ArticleThe Biosimilar CT-P13 Infliximab Is More Immunogenic Than the Original Infliximab In Iraqi Patients with Ankylosing Spondylitis
ArticleThe Biosimilar CT-P13 Infliximab Is More Immunogenic Than the Original Infliximab In Iraqi Patients with Ankylosing Spondylitis
ArticlePharmaceutical Innovation and its Implications for Nursing, Medical Records, and Diagnostics Practice
ArticlePharmaceutical Innovation and its Implications for Nursing, Medical Records, and Diagnostics Practice